INCRETIN MIMETICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Incretin Mimetics Market, By Drug Type (Exenatide, Liraglutide, Sitagliptin, Saxagliptin, Alogliptin , Others), By Disease Indication (Type 2 Diabetes Mellitus (T2DM) , Weight Management , Others), By Distribution Channel (Online Pharmacies , Retail Pharmacies , Hospital Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

Published In : Feb 2024
Code : CMI6694
Pages :157
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Incretin Mimetics Market Concentration, By Players

Close-monitor your Competitor's Move, Request sample copy

Growing awareness of benefits of incretin mimetics

With incretin mimetics having been on the market for over a decade, there is significant awareness within the medical community as well as among patients about the clinical profile and advantages of this class of anti-diabetes drugs. Extensive clinical research has demonstrated the ability of incretin mimetics to reduce HbA1c levels while minimizing the risks of hypoglycemia and weight gain that are commonly associated with other glucose-lowering medications. Post-marketing studies have also established their cardiovascular safety. These key benefits compared to older drugs have generated much interest among physicians who prefer to initiate patients on incretin mimetics as first-line injectable therapy when oral drugs are not sufficient. Additionally, the risk and complications associated with hyperglycemia and poorly controlled diabetes are now better appreciated by patients. They are more proactively involved in managing their condition and open to therapies that can help achieve optimal glucose control safely.

Key Players Insights